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Summary 
The sphingomyelin pathway, which is initiated by 
sphingomyelin hydrolysis to generate the second mes- 
senger ceramide, signals apoptosis for tumor necrosis 
factor a, Fas, and ionizing radiation. In the present 
studies, the anticancer drug daunorubicin also stimu- 
lated ceramide elevation and apoptosis in P388 and 
U937 cells. Cell-permeable analogs of ceramide, but 
not other lipid second messengers, mimicked daunoru- 
bicin in inducing apoptosis. Daunorubicin-stimulated 
ceramide elevation, however, did not result from 
sphingomyelin hydrolysis, but rather from de novo 
synthesis via activation of the enzyme ceramide syn- 
thase. An obligatory role for ceramide synthase was 
defined, since its natural specific inhibitor, fumonisin 
B1, blocked daunorubicin-induced ceramide elevation 
and apoptosis. These studies demonstrate that cera- 
mide synthase activity can be regulated in eukaryotes 
and constitute definitive evidence for a requirement 
for ceramide elevation in the induction of apoptosis. 
Introduction 
Anticancer drugs have been shown to target diverse intra- 
cellular elements in conferring a lethal effect in mamma- 
lian cells. Some drugs affect the structure or function of 
DNA or RNA; others interfere with enzymes involved in 
folate, purine, or pyrimidine metabolism, microtubular 
function, or the function of the mitotic spindle (Calabresi 
and Chabner, 1990; Epstein, 1990). The prevailing hypoth- 
esis on the lethal mechanism of drug action suggests that 
these insults lead to DNA dysfunction and failure to main- 
tain normal replication (Epstein, 1990). This hypothesis 
was challenged recently by studies that showed that, irre- 
spective of the intracellular target, many of these drugs 
induce a common final death pathway, known as apoptosis 
or programmed cell death (Searle et al., 1975; Dyson et 
al., 1986; Kaufmann, 1989; Barry et al., 1990; Hickman, 
1992; Sen and D'lncalci, 1992; Ling et al., 1993; Sklada- 
nowski and Konopa, 1993). Apoptosis is conceptualized 
as an inducible preprogrammed pathway of sequential bio- 
chemical events that are only partially known, leading to 
activation of calcium- and mag nesium-dependent endonu- 
cleases that cleave the nuclear chromatin at selective in- 
ternucleosomal inker sites (Wyllie, 1980; Vaux, 1993). 
Signals generated at the membrane of affected cells acti- 
vate neighboring intact cells and infiltrating macrophages 
to phagocytize the dying cell and its disintegrating nucleus 
(Duvall et al., 1985). While the nature of drug interactions 
with cellular targets has been extensively studied, the 
mechanism by which chemotherapeutic agents induce the 
apoptotic pathway remains unclear (Dive and Wyllie, 1993). 
Activation of the apoptotic pathway by tumor necrosis 
factor a (TNF~), Fas, and ionizing radiation was shown to 
be mediated through the sphingomyelin signal transduc- 
tion pathway (Obeid et al., 1993; Jarvis et al., 1994a; Hai- 
movitz-Friedman et al., 1994; Cifone et al., 1994). The 
sphingomyelin pathway is a ubiquitous signaling system 
that links specific cell-surface receptors and environmen- 
tal stresses through to the nucleus (Kolesnick and Golde, 
1994; Hannun, 1994). This pathway is initiated by hydroly- 
sis of the phospholipid sphingomyelin, which is preferen- 
tially concentrated in the plasma membrane of mamma- 
lian cells. Sphingomyelin hydrolysis occurs within seconds 
to minutes after stimulation via the action of sphingomye- 
lin-specific forms of phospholipase C, termed sphingomy- 
elinases, to generate ceramide. Ceramide then serves as 
a second messenger in this system, leading to apoptotic 
DNA degradation. The specificity of ceramide as a second 
messenger for apoptosis was demonstrated by the fact 
that cell-permeable ceramide analogs, but not analogs of 
other lipid second messengers, including 1,2-diacylgtyc- 
erol, arachidonic acid, and phosphatidic acid, were able 
to recapitulate the effects of TNFm Fas, and ionizing radia- 
tion and induce apoptosis directly. Further, dihydrocera- 
mide, which lacks the trans double bond at C4-C5 of the 
sphingoid base backbone, did not induce apoptosis, indi- 
cating that the induction of apoptosis by ceramide was 
stereospecific. 
Utilization of the sphingomyelin pathway for induction 
of the apoptotic response has now been demonstrated in 
a large number of mammalian cells. It was reported in 
TNF~-stimulated U937 monoblastic and HL-60 promyelo- 
cytic leukemia cells and L929/LM and WEHI-164/13 hu- 
man fibrosarcoma cells (Obeid et al., 1993; Jarvis et al., 
1994a). It also mediates apoptosis in response to Fas liga- 
tion in Jurkat, U937, and several other human tumor cells. 
Further, transfection of Fas into murine P815 mastocy- 
toma'and L1210 lymphocytic leukemia cell lines conferred 
apoptotic ell death via the sphingomyelin pathway (Cifone 
et al., 1994; Gulbins et al., 1995). Haimovitz-Friedman et al. 
(1994) reported that rapid activation of a membrane-bound 
neutral sphingomyelinase mediates apoptosis in primary 
cultures of bovine aortic endothelial cells exposed to ioniz- 
ing radiation. 
The details of the apoptotic pathway downstream of cer- 
amide generation are not fully known, although several 
distinct immediate targets for the action of ceramide have 
been identified. These include a 97 kDa proline-directed 
serine/threonine protein kinase, termed ceramide-acti- 
vated protein kinase (Mathias et al., 1991; Joseph et al., 
Cell 
406 
1993), a ceramide-activated protein phosphatase, which is 
a member of the serine/threonine phosphatase 2A family 
(Dobrowsky et al., 1993), protein kinase C-~ (Lozano et 
al., 1994), and the putative guanine nucleotide xchange 
factor Vav (Gulbins et al., 1994). Activation of downstream 
factors including Raf-1 (Liu et al., 1994), mitogen-activated 
protein (MAP) kinase (Raines et al., 1993), and NF-KB 
(Yang et al., 1993; Machleidt et al., 1994) have also been 
demonstrated, although their role in the apoptotic pathway 
remains unknown. 
In the present study, we report an alternative mecha- 
nism for generating ceramide and initiating apoptosis in 
daunorubicin-treated cells. Daunorubicin is an anthracy- 
cline used in the treatment of leukemia. The anthracy- 
clines act on mammalian cells by multiple mechanisms 
involving cell-membrane ffects, intercalation into DNA, 
and inhibition of topoisomerase II (Calabresi and Chabner, 
1990). Several anthracyclines were reported to induce 
apoptosis in vitro and in vivo, but the mechanism of this 
action remains unknown (Anilkumar et al.,J 992; Thakkar 
and Potten, 1992; Ling et al., 1993; Skladanowski and 
Konopa, 1993; Zwelling et al., 1993; Smith et al., 1994). 
The present studies show that daunorubicin stimulates a 
progressive elevation of cellular ceramide and apoptosis 
in murine P388 lymphocytic and human U937 monoblastic 
leukemia cells. However, daunorubicin-induced ceramide 
elevation did not result from sphingomyelin degradation 
by a sphingomyelinase, but rather from stimulation of cera- 
mide synthesis by the enzyme ceramide synthase. Cera- 
mide synthesis appeared obligatory for daunorubicin- 
induced apoptosis, since fumonisin B1, a natural specific 
inhibitor of ceramide synthase, blocked daunorubicin- 
induced ceramide elevation and apoptosis. This finding 
demonstrates that the activity of ceramide synthase can 
be regulated in eukaryotes and provides evidence for a 
requirement for ceramide in the induction of the apoptotic 
process. These data also identify stimulation of ceramide 
synthesis as an alternative to sphingomyelin breakdown 
in ceramide signaling of apoptotic cell death. 
Results 
Daunorubicin Induces Apoptosis in P388 
and U937 Cells 
Figure 1A shows that treatment of P388 cells with 1 ~M 
daunorubicin resulted in apoptotic DNA degradation, de- 
tected by the typical DNA ladder consisting of 180 bp frag- 
ments by neutral agarose gel electrophoresis. DNA lad- 
dering was routinely observed within 12 hr of treatment 
with daunorubicin and with daunorubicin concentrations 
as low as 50 nM (data not shown). Incubation of P388 cells 
with 1 I~M daunorubicin also resulted in the appearance of 
typical morphological changes of apoptosis upon staining 
with the DNA-specific fluorochrome bis-benzimide trihy- 
drochloride (Figure 1B). These include condensation of 
chromatin, its compaction along the periphery of the nu- 
cleus, and segmentation of the nucleus. A time course of 
nuclear fragmentation demonstrated an increase in the 
number of apoptotic ells, which became apparent at 6-8 
hr after the addition of daunorubicin to the culture medium 
(Figures 1C and 2C). At 24 hr, nearly 80% of the cells 
exhibited apoptotic changes. This apoptotic effect was 
also observed with as little as 0.05 p.M daunorubicin, and 
a plateau of 80% apoptotic ells was observed with a dose 
of 0.5-1.0 ~M (data not shown). The EDso of daunorubJcin- 
induced apoptosis at 24 hr was 0.3 ~M. In this context, it 
should be noted that therapeutic plasma levels of daunoru- 
bicin were shown to range between 0.1 pM and 0.4 ~M 
(AIberts et al., 1971; Speth et al., 1989). 
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Figure 1. AgaroseGel Electrophoresisof DNA 
and Nuclear Morphology Following Treatment 
of P388 Cells with Daunorubicin 
(A) Gel electrophoresis of DNA. Cells, at an 
initial density of 0.75 × 108 per milliliter, were 
treated with 1 ~M daunorubicin. After 21 hr, 10 
ml of cell suspension was pelleted and lysed 
in Nicoletti lysis buffer (10 mM Tris [pH 7.5], 100 
mM NaCI, 1 mM EDTA, 1% sodium dodecyl 
sulfate, and 50 ~g/ml proteinase K), and geno- 
mic DNA was extracted. DNA was loaded (10 
I~g per lane) and subjected to agarose gel elec- 
trophoresis. 
(B) Morphological lterations of chromatin. 
Cells were treated with saline (a) or 1 ;~M 
daunorubicin (b) as in (A). After 22 hr, cells 
were fixed with paraformaldehyde, stained with 
the DNA-specific fluorochrome bis-benzimide 
(Hoechst 33258), and viewed at a magnifica- 
tion of 71 x. 
(C) Quantification of nuclear morphologic 
changes with time following incubation with 1 
~M daunorubicin. Cells with three or more 
chromatin fragments were considered apop- 
totic. Similar esults were observed in four ex- 
periments. Each value represents he mean ___ 
range of duplicate determinations of 500 cells 
each. 
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Figure 2. AgaroseGelElectrophoresisofDNA 
and Alterations of Nuclear Morphology Follow- 
ing Treatment of P388 Cells with Lipid Second 
Messenger Analogs 
(A) Gel electrophoresis of DNA. Cells, at an 
initial density of0.5 x 108 per milliliter, were 
treated with 100 p.M C2-ceramide (N-acetyl 
sphingosine) or diluent (0.2% dimethyl sulfox- 
•de [DMSO]). After 21 hr, genomic DNA was 
subjected to agarose gel electrophoresis. 
(B) Morphological alterations of chromatin. 
Cells were treated with 0.2% DMSO (control) 
(a) or 100 t~M C2-ceramide (b). After 12 hr, cells 
were fixed, and their chromatin was stained 
with bis-benzimide. 
(C) Quantification of nuclear morphologic 
changes with time following incubation with 1 
I~M daunorubicin, 100 pM C2-ceramide, 100 
~M C8-ceramide (N-octanoyl sphingosine), 
100 I~M C2-dihydroceramide (N-acetyl dihydro- 
sphingosine), or 0.2% DMSO (control). 
(D) Quantification of nuclear morphologic 
changes following incubation with 1 I~M daun- 
orubicin, 100 I~M 1,2-dioctanoyl-sn-glycerol (di- 
acylglycerol), 100 I~M 1,2-dioctanoyl-sn- 
glycero-3-phosphate (phosphatidic acid), 100 
p.M arachidonic acid, or 0.2% DMSO (control). 
Values in both (C) and (D) represent mean -+ 
range of duplicate determinations of 500 cells 
each. Similar results were observed in two ex- 
periments. 
Investigations were also performed with U937 human 
monoblastic leukemia cells to determine whether the ef- 
fects observed in P388 cells might be extrapolated to other 
systems. Nearly identical results were obtained. In U937 
cells, daunorubicin induced dose-dependent apoptosis at 
24 hr of incubation. In control cells, 2% --+ 1% of the 
population was apoptotic. As little as 100 nM daunorubicin 
was effective, increasing apoptosis to 10% - 1%, and 
a maximal effect (>80% apoptosis) was achieved with 1 
I~M daunorubicin. The LDs0 for this effect was 200 nM. 
Ceramide Mimics Daunorubicin 
in Inducing Apoptosis 
Because previous tudies reported that the apoptosis in- 
duced by TNF~, Fas, and ionizing radiation is mediated 
via elevation of intracellular ceramide, we tested whether 
addition of cell-permeable ceramide analogs is associated 
with apoptosis in P388 cells. Figure 2A shows that treat- 
ment of P388 cells with a maximally effective concentra- 
tion of C2-ceramide (100 pM) mimicked daunorubicin in 
inducing oligonucleosomal DNA fragmentation on aga- 
rose gel electrophoresis, as well as in the appearance of 
typical apoptotic changes on bis-benzimide staining (Fig- 
ure 2B). Similar morphological changes were observed 
with the C8-ceramide analog at a concentration of 100 
p,M (Figure 2C). Concentrations of synthetic ceramides 
as low as 10 pM were found to induce apoptosis. The 
development of morphological changes after treatment 
with ceramide analogs proceeded more rapidly than the 
effects induced by daunorubicin. However, the maximal 
effects at 24 hr were quantitatively similar for ceramide 
analogs and daunorubicin (Figure 2C). In contrast, treat- 
ment with an equimolar concentration (100 I~M) of the im- 
mediate precursor of ceramide, dihydroceramide, which 
lacks the trans double bond at C4-C5 of the sphingoid 
base backbone, resulted in only a minimal apoptotic re- 
sponse (Figure 2C). Furthermore, other celt-permeable an- 
alogs of lipid second messengers, including the 1,2-diacyi- 
glycerol 1,2-dioctanoyl-sn-glycerol, the phosphatidic acid 
1,2-dioctanoyl-sn-giycero-3-phosphate, nd free arachi- 
donic acid, did not induce apoptosis (Figure 2D). Nearly 
identical results have been reported in U937 cells (Jarvis 
et al., 1994a). These data indicate specificity for ceramide 
in the induction of apoptosis. 
Daunorubicin Induces Elevation 
in Intracellular Ceramide 
The ability of ceramide to mimic the action of daunorubicin 
suggests that ceramide may be a mediator of daunoru- 
bicin-induced apoptosis in P388 cells. To explore this hy- 
pothesis further, we investigated the ability of daunoru- 
bicin to increase the intracellular levels of ceramide. Figure 
3A shows that treatment of P388 cells with 10 I~M daunoru- 
bicin indeed resulted in an increase in ceramide levels. 
Generation of ceramide was detectable by 4 hr and 
reached a plateau at 8 hr. Qualitatively similar results were 
obtained in four studies performed with 200 nM daunoru- 
bicin, it should be noted that ceramide elevation preceded 
in time the appearance of the apoptotic nuclear changes, 
which are shown in Figure lB. The effect of daunorubicin 
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Figure 3. Changes in Ceramide and Diacylglycerol Levels in Re- 
sponse to Daunorubicin 
(A) Time course. P388 cells at a density of 1 x 106 per milliliter were 
treated with 10 p.M daunorubicin. At the indicated times, cell number 
was determined by Coulter counter, and cells were washed twice with 
ice cold phosphate-buffered saline (PBS) and extracted with chtoro- 
form:methanol:l N HCI (100:100:1). Lipid extracts were assayed for 
ceramide and diacytglycerol (DG) by the diacylgtycerol kinase reaction. 
Each value represents mean +_ SEM of triplicate determinations from 
three experiments for ceramide and two experiments for diacylglycerol. 
(B) Dose response to daunorubicin. Cells were treated with the indi- 
cated doses of daunorubicin for 10 hr. Lipids were quantified as in 
(A). Each value represents mean _+ SEM of triplicate determinations 
from three experiments. 
Asterisks indicate p < 0.001 compared with pretreatment values. 
The baseline levels of these lipids did not change significantly during 
these studies. 
to increase ceramide levels was specific, as daunorubicin 
did not induce an elevation in the level of the lipid second 
messenger 1,2-diacylglycerol. Elevation of ceramide by 
daunorubicin was dose-dependent (Figure 3B). Statisti- 
cally significant elevation was detected at drug concentra- 
tions as low as 100 nM (p < 0.001). The effect of daunoru- 
bicin to increase cellular ceramide was also evaluated in 
U937 cells. As in P388 cells, ceramide levels did not in- 
crease until 4 hr after addition of 10 I~M daunorubicin and 
increased linearly thereafter to a maximum of 6-fold of 
control by 12 hr. 
The Mechanism of Ceramide Generation 
Previous studies on the involvement of ceramide in activa- 
tion of the apoptotic pathway by TNF~, Fas, and ionizing 
radiation reported that intracellular ceramide elevation re- 
sulted from hydrolysis of the phospholipid sphingomyelin 
by a sphingomyel inase (Obeid et al., 1993; Jarvis et al., 
1994a; Haimovitz-Friedman et al., 1994; Cifone et al., 
1994). Activation of sphingomyel inase and ceramide gen- 
eration occurred within seconds to minutes after exposure 
to these agents. Figure 3A shows that the pattern of cera- 
mide activation in P388 cells after exposure to daunoru- 
bicin did not fol low the TNF(z and radiation model. In fact, 
measurements of ceramide and sphingomyelin levels 
failed to show a change in the levels of these lipids within 
the first 30 s to 120 rain after addition of daunorubicin to 
the culture medium (data not shown). Further, at 4 -8  hr, 
when ceramide levels were increasing (Figure 3A), there 
was a concomitant rise rather than a decrease in cellular 
sphingomyelin content (Figure 4). These observations sug- 
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Figure 4. Changes in Sphingomyelin Levels in Response to Daunoru- 
bicin 
P388 cells were incubated with [3H]choline (1 ~.Ci/ml) for three cell 
doublings to label cellular sphingomyelin. Cells at a density of 1 x 
10 ~ per milliliter were treated with 10 p.M daunorubicin. At the indicated 
times (closed circles), cell number was determined by hemacytometer, 
and cells were then extracted with chloroform:methanohl N HCI (100: 
100:1). Lipid extracts were subjected to mild alkaline hydrolysis, and 
sphingomyelin was resolved by thin-layer chromatography. Baseline 
sphingomyelin mass was determined by lipid phosphorus measure- 
ments. Each value represents mean _+ SEM of triplicate determina- 
tions. Single and double asterisks indicate p < 0.05 and p < 0.01 
compared with pretreatment values, respectively. Similar results were 
obtained in three experiments. 
gested that ceramide elevation in daunorubicin-treated 
P388 cells is not associated with activation of a sphingo- 
myelinase. 
To examine further the mechanism of ceramide genera- 
tion after daunorubicin stimulation, we designed experi- 
ments to evaluate the effects of daunorubicin on the de 
novo synthesis of ceramide. P388 cells were incubated 
with [1-14C]stearic acid, and the rate of its incorporation 
into ceramide was measured. A similar approach was uti- 
lized to assess the effect of retinoic acid on ceramide syn- 
thesis in intact rat pituitary cells (Kalen et al., 1992). Figure 
5A shows that cells treated with daunorubicin demonstrate 
increased synthesis of ceramide, manifested by enhanced 
incorporation of radiolabeled stearic acid into ceramide. In 
contrast, incorporation of [14C]stearic acid into total cellular 
lipids was not increased in daunorubicin-treated cells (data 
not shown). 
Ceramide synthesis is mediated by the enzyme cera- 
mide synthase, also known as sphinganine N-acyl trans- 
ferase (EC 2.3.1.24) (Merrill and Jones, 1990). This en- 
zyme catalyzes the condensation of sphinganine and fatty 
acy l -coenzyme A to form dihydroceramide, which is rap- 
idly oxidized to form ceramide. To evaluate the role of 
ceramide synthase in daunorubicin action, we treated 
P388 cells with daunorubicin (10 #M) for 6 hr and prepared 
microsomal membranes.  Ceramide synthase activity was 
assayed in vitro under conditions determined as linear for 
time and enzyme concentration and in which substrate 
was not rate limiting (data not shown). Figure 5B shows 
kinetics of ceramide synthase activity using varying con- 
centrations of sphinganine. Daunorubicin treatment en- 
hanced the activity of ceramide synthase (p < 0.01 versus 
control, n = 4). Eadie-Hofstee transformation of the data 
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Figure 5. Evaluation of the Ceramide Synthetic Pathway in Intact 
Cells and Ceramide Synthase Activity Determination In Vitro 
(A) Evaluation of t he ceramide synthetic pathway. Rate of incorporation 
of [1-t4C]stearic acid into ceramide was examined in intact cells as 
follows: P388 cells at an initial density of 1.0 x 106 per milliliter were 
treated with 10 pM daunorubicin for 6 hr, washed, and resuspended 
at a density of 120 x 108 per milliliter in buffered saline solution (BSS). 
[1-1"C]stearic acid (0.2 #.Ci per 108 cells) was dried under N2, resus- 
pended in BSS with sonication, and added to the cell suspension to 
start the reaction. At the indicated times, lipids were extracted and 
subjected to mild alkaline hydrolysis as described above. [14C]cera- 
mide was resolved by thin-layer chromatography, detected by comigra- 
tion with ceramide standards, and quantified by liquid scintillation 
counting. Nonspecific incorporation was determined at 0°C. Values 
were fit to the equation y = ax  ~ and yielded correlation coefficients 
of 0.997 and 0.963 for daunorubicin-treated and control curves, re- 
spectively. Similar results were obtained in two experiments. 
(B) Ceramide synthase activity. Cells were treated with daunorubicin 
as in (A), and microsomal membranes were prepared. Microsomal 
membrane protein (75 pg) was incubated in a reaction mixture con- 
taining 2 mM MgCI2, 20 #M defatted bovine serum albumin, indicated 
concentrations of sphinganine, 70 #,M unlabeled palmitoyl-coenzyme 
A, and 0.2 pCi of [1-1"C]palmitoyl-coenzyme A. The reaction was incu- 
bated at 37°C for 1 hr, and then lipids were extracted using 2 ml 
of chloroform:methanol (1:2). Dihydroceramide was resolved using 
thin-layer chromatography, detected by comigration with ceramide 
standards, and quantified by liquid scintillation counting. Values repre- 
sent mean of determinations from four separate experiments. 
(C) Determination of Ku and V=,× from (B) utilizing Eadie-Hofstee 
analysis. 
revealed a 70% increase in Vmax (Figure 5C) and little or no 
change in the KM. A similar increase in ceramide synthase 
activity was observed in U937 cells (data not shown). Ki- 
netics were also performed using varying concentrations 
of the substrate palmitoyl -coenzyme A and showed that 
daunorubicin induced a similar increase in the Vmax with 
no change in the KM for this lipid of 5 ~M. At 200 nM 
daunorubicin, the activity was enhanced 30% (data not 
shown)• A small (less than 10%) increase in ceramide syn- 
thase activity was detected as early as 1 hr after addition 
of daunorubicin to P388 cells, and the activity increased 
linearly (r = 0.96) for 6 hr. There was little further increase 
in ceramide synthase activity thereafter. Hence, changes 
in ceramide synthase were progressive and preceded ele- 
vation in the sphingomyelin and ceramide levels (see Fig- 
ures 3A and 4), and apoptosis (see Figure 1C). This obser- 
vation strongly suggests that the ceramide synthetic 
pathway is enhanced through activation of ceramide syn- 
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Figure 6. The Structure of Fumonisin B1 and Its Effect on Ceramide 
Generation 
(A) Structures of sphingosine, sphinganine, and fumonisin BI. 
(B) Effect of fumonisin B1 on daunorubicin-induced ceramide eleva- 
tion. For these studies, P388 cells were handled as in Figure 3, except 
for a 30 min pretreatment with 100 pM fumonisin B1 (FB1) prior to 
addition of 200 nM daunorubicin. The values represent mean -_+ SD 
of triplicate determinations from one of five similar studies. 
thase. Further, preliminary studies suggest that this effect 
may be specific for daunorubicin, since LDg0 doses of vin- 
cristine (0.1 #M), methotrexate (0.2 #M), etoposide (3 #M), 
and c is -p la t inum (50 #M) did not stimulate ceramide syn- 
thase at 7 hr, a t ime immediate ly  preceding apoptosis 
and at which daunorubicin- induced synthase activity was 
max imal  
Fumonisin B1 Inhibits Daunorubicin-lnduced 
Apoptosis 
To evaluate further the notion that ceramide synthase is 
involved in daunorubicin-induced ceramide elevation and 
apoptosis, we performed experiments with fumonisin BI .  
Fumonisin B1 is a natural product of the fungus Fusarium 
monil iforme that acts as a mycotoxin in mammalian cells 
(Wang et al., 1992). Consumption of food contaminated 
with this fungus causes leucoencephalomalacia and hep- 
atotoxicity in horses, pulmonary edema in pigs, and liver 
cancer in rats. These diseases can be reproduced by in- 
gestion of purified fumonisins (Wang et al., 1992). Fumoni- 
sin B1 has substantial structural similarities to sphinganine 
and sphingosine (Figure 6A). Merrill and coworkers pro- 
vided compell ing evidence that fumonisin B1 is a potent 
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and specific inhibitor of ceramide synthase and that this 
activity mediates the deleterious effects of F. moniliforme 
on livestock (Wang et al., 1991). Other major enzymes 
of sphingoid base metabolism, such as serine palmitoyl 
transferase, the regulatory enzyme for sphingoid base 
synthesis, and sphingosine kinase, the enzyme initiating 
sphingoid base disposal, are not affected by fumonisin B1 
(Merrill et al., 1993). 
Initial studies evaluated the effect of fumonisin B1 on 
ceramide synthase activity in vitro using a concentration 
of sphinganine (10 ~M) sufficient for maximal enzymatic 
activity. Fumonisin (0.1-50 ~M) induced dose-dependent 
inhibition of ceramide synthase activity. As little as 0.1 
I~M fumonisin was effective, and complete inhibition was 
achieved with 5 t~M fumonisin. The ICs0 was determined 
to be 0.2 p.M fumonisin BI. 
Treatment of intact P388 cells with doses of fumonisin 
B1 up to 100 llM for as long as 24 hr did not affect the 
rate of cell proliferation or cell viability (data not shown). 
However, preincubation with fumonisin B1 (100 t~M) for 
30 min prior to addition of daunorubicin (200 nM) inhibited 
daunorubicin-induced ceramide elevation by 80% (Figure 
6B). Similar results were obtained with 25 ~M fumonisin 
B1 and if fumonisin B1 was added up to 7 hr prior to dauno- 
rubicin (data not shown). Concomitantly, fumonisin B1 in- 
hibited daunoru bicin-induced apoptosis. Figure 7A shows 
that 25 llM fumonisin B1 blocked the induction of DNA 
fragmentation by 200 nM daunorubicin at 12 hr of incuba- 
tion. Figure 7B shows that fumonisin B1 also inhibited the 
development of apoptotic nuclear changes produced by 
a 24 hr incubation with daunorubicin. At dose levels of 
both 25 p.M and 100 p.M, fumonisin B1 inhibited 80% and 
60% of the apoptotic lethal effect produced by 200 nM and 
300 nM daunorubicin, respectively (Figure 7C). Fumonisin 
abolished apoptosis even when added up to 2 hr after 
daunorubicin. However, fumonisin was completely inef- 
fective if addition was delayed for 4 hr or longer after 
daunorubicin. Increasing the dose of daunorubicin to 
greater than 500 nM also abrogated the inhibitory effect 
of fumonisin B1. In contrast, fumonisin B1 (25 llM) did not 
block C8-ceramide-induced apoptosis at any concentra- 
tion from 10-50 ~M (data not shown). These investigations 
indicate that fumonisin B1 acts as an inhibitor of ceramide 
generation rather than a general antagonist of apoptosis. 
Similar to the effect on P388 cells, fumonisin B1 blocked 
the effect of daunorubicin in U937 cells, abolishing 
apoptosis for all concentrations of daunorubicin up to 200 
nM (Figure 7D). In contrast, apoptosis induced by a near- 
maximal concentration of TNF (10 nM) was not affected 
by fumonisin treatment. Even though fumonisin abrogated 
daunorubicin-induced apoptosis, growth inhibition was not 
reversed, indicating that apoptosis and growth inhibition 
are mediated through distinct daunorubicin-activated 
mechanisms. The most parsimonious explanation for 
these results is that fumonisin acts to inhibit ceramide 
synthase directly, but does not alter the daunorubicin- 
induced DNA damage responsible for growth inhibition. 
The ability of a specific ceramide synthase inhibitor to an- 
tagonize daunorubicin-induced apoptosis defines a re- 
quirement for ceramide generation in this process. 
÷ 
A ~ ~ ~ B 
C 
40- [ ]  FB1 (1 ~M) 40 [ ]  FB1 (25 llM) 
[ ]  FB1 {25 pM) 
"~ 30 • FB1 (100 FM) 30 °L !k ~ .20  ~0 
10 10- 
0 o 100 200 300 Control 160 .M n n 
Daunorubicin (nM) Oaun TNF~ 
Figure 7. Effect of Fumonisin B1 on DNA Fragmentation a d Nuclear 
Morphology 
(A) Get electrophoresis of DNA. P388 cells, at an initial density of 
0.5 x 106 per milliliter, were treated with 200 nM daunorubicin or 
with daunorubicin plus 25 pM fumonisin B1 (FB1). Pretreatment with 
fumonisin was for 7 hr. After 12 hr, genomic DNA was subjected to 
gel electrophoresis a in Figure 1A. Similar results were obtained in 
five separate studies using cells stimulated for 12-20 hr with daunoru- 
bicin. 
(B) Alterations of nuclear morphology. P388 cells were treated with 
saline (a), 25 llM fumonisin B1 (b), 200 nM daunorubicin (c), or both 
fumonisin B1 and daunorubicin (d). After 24 hr, cells were fixed with 
paraformaldehyde and stained with bis-benzimide. 
(C) Quantification of nuclear morphologic changes following incuba- 
tion with varying concentrations of daunorubicin and fumonisin B1 
(FB1) for 24 hr. Similar results were observed in four experiments. 
Each value represents mean ± range of duplicate determinations of 
500 cells each. 
(D) Effect of fumonisin B1 (FB1) on daunorubicin- and TNF-induced 
apoptosis in U937 cells at 24 hr. These data (mean ± SD) are derived 
from two studies performed as escribed above for P388 cells. 
Discussion 
The present studies provide evidence that generation of 
ceramide mediates daunorubicin-induced apoptosis. Cer- 
amide generation preceded the onset of apoptosis, and the 
dose dependencies for ceramide elevation and apoptosis in 
response to daunorubicin correlated closely. The cera- 
mide response to daunorubicin was selective, as the level 
of the second messenger 1,2-diacylglycerol did not in- 
crease. The apoptotic response was specific for ceramide, 
as other lipid second messengers failed to initiate this 
event. The effect of ceramide was stereospecific, since 
dihydroceramide, a closely related structure, was without 
effect. Ceramide generation and apoptosis occurred 
within the therapeutic range of daunorubicin concentra- 
tions in P388 cells, consistent with the notion that these are 
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clinically relevant processes (Alberts et al., 1971 ; Speth et 
al., 1989). 
The mechanism of ceramide generation in response to 
daunorubicin did not comply with the sphingomyelinase 
activation model described for TNFc~-, Fas-, and radiation- 
induced apoptosis. In the present study, ceramide eleva- 
tion resulted from de novo synthesis of ceramide via the 
enzyme ceramide synthase. The 70% increase in the theo- 
retical maximal velocity of the enzyme from 7 to 12 pmol/ 
min per 108 cells is far more than sufficient o account for 
the sustained 90 pmol per 106 cell rise in ceramide levels. 
These studies demonstrate that ceramide synthase activ- 
ity can be regulated in eukaryotic cells. Further, these 
studies describe a biological function for this enzyme asso- 
ciated with its biochemical role in ceramide formation. The 
inhibition of daunorubicin-induced ceramide generation 
and apoptosis by the mycotoxin fumonisin B1, and the 
ability of ceram ide analogs to restore apoptosis to fumoni- 
sin-treated cells, provides definitive vidence for a cause- 
and-effect relationship of these events. These studies, 
however, do not imply that other chemotherapeutic agents 
utilize the ceramide synthase mechanism. In fact, prelimi- 
nary studies performed with a number of chemotherapeu- 
tic agents of different classes failed to show enhanced 
ceramide synthase activity. Further, an increase in cellular 
ceramide via activation of neutral sphingomyelinase was 
reported in HL-60 cells following treatment with arabinofur- 
anosylcytosine (ara-C), although no information was pro- 
vided concerning the role of ceramide generation in the 
death of these cells (Strum et al., 1994). The present stud- 
ies do not rule out a localized activation of sphingomyelin- 
ase after daunorubicin treatment. In this regard, a small 
(approximately 30%)increase in neutral and acid activities 
was observed at 4 hr. The neutral activity returned to the 
resting levels by 6 hr, but the increase in acid activity per- 
sisted (data not shown). 
The stimulation of ceramide synthase to generate cera- 
mide in response to daunorubicin did not become appar- 
ent until 4-6 hr of incubation with the drug. Although no 
information is presently available concerning the mecha- 
nism of daunorubicin stimulation of ceramide synthase 
activity, this time course is consistent with new protein 
synthesis. In this regard, it has been shown by several 
investigators that daunorubicin- and doxorubicin-induced 
apoptosis can be blocked by the protein synthesis inhibi- 
tor, cycloheximide (Thakkar and Potten, 1992; Ling et al., 
1993; Skladanowski and Konopa, 1993). At the present 
time, the molecular probes required to investigate whether 
the increased enzymatic activity of ceramide synthase re- 
sults from its gene activation as a stress response to DNA 
damage by daunorubicin or as a posttranscriptional event 
are not available. Whatever may be the mechanism of 
synthase activation during daunorubicin-induced apoptosis, 
its apparent requirement contrasts with the lack of correla- 
tion between daunorubicin-induced cytotoxicity and either 
DNA damage or topoisomerase inhibition as reviewed by 
Epstein (1990). 
While ceramide generation is the mechanism for induc- 
tion of apoptosis in response to treatment with a variety 
of lethal agents, not all instances of ceramide elevation 
are associated with apoptosis. Hannun and coworkers 
showed that ceramide generation mediated monocyte dif- 
ferentiation of HL-60 cells (Okazaki et al., 1989). Mathias 
et al. (1993) reported that the sphingomyelin pathway is 
a major signaling system for interleukin-1 (IL-1) in EL4 T 
helper cells, mediating IL-l-induced IL-2 secretion. Bou- 
cher et al. (1995) recently reported that activation of the 
sphingomyelin pathway in CD28-stimulated human Jurkat 
T cells and in primary cultures of mouse splenic T cells 
leads to NF-•B activation and mitogenesis, rather than 
apoptosis. Similarly, Spiegel and coworkers demonstrated 
ceramide-stimulated mitogenesis in 3T3 fibroblasts (Oli- 
vera et al., 1992). Ceramide thus seems to serve as a 
pleiotropic biologic activator, capable of inducing several 
cellular functions. In this regard, Kronke and coworkers 
have provided evidence that mammalian cells may utilize 
two separate forms of sphingomyelinase, an acidic and a 
neutral isoform, for ceramide generation (Wiegmann et 
al., 1994). These sphingomyelinases were activated by 
different domains of the 55 kDa TNF receptor and trig- 
gered distinct downstream signaling pathways. These in- 
vestigators postulated that the neutral sphingomyelinase, 
which may be plasma-membrane bound, initiates the MAP 
kinase cascade, whereas the acidic isoform, which is ap- 
parently endosomal, initiates apoptosis. Ceramide syn- 
thase has been localized to the endoplasmic reticulum of 
liver cells (Mandon et al., 1992; Hirschberg et al., 1993), 
suggesting that ceramide generation may occur in yet an- 
other intracellular site. In this regard, cerami-de, like diacyl- 
glycerol, can rapidly redistribute across a membrane bi- 
layer and, hence, may act at additional intracellular sites. 
Whether inducible ceramide generation via ceramide syn- 
thase is involved in biochemical processes other than 
apoptosis remains to be explored. 
In some cell types, failure to induce an apoptotic response 
may be associated with activation of an anti-apoptotic sig- 
naling pathway. 1,2-Diacylgtycerot or its analog phorbol 
ester inhibits the apoptotic response to ceramide in virtu- 
ally every cell system tested. Obeid et al. (1993) reported 
that phorbol ester pretreatment of U937 monoblastic leu- 
kemia cells blocked TNF- and ceramide-induced apoptosis. 
Similarly, Jarvis et al. (1994b) reported that pretreatment 
with synthetic 1,2-diacylglycerol, phorbol ester, or exoge- 
nous phospholipase C blocked TNF- and ceramide-medi- 
ated apoptosis, whereas down-regulation of protein kinase 
C by prolonged exposure to phorbol ester enhanced TNF- 
and ceramide-mediated apoptosis in a HL-60 cell variant. 
Further, Haimovitz-Friedman et al. (1994) showed that phor- 
bol ester blocked ionizing radiation-induced apoptosis by 
inactivation of a sphingomyelinase in primary cultures of 
bovine aortic endothelial ceils. Hence, apoptosis may be 
reciprocally regulated by the lipid second messengers cer- 
amide and 1,2-diacylglycerol. Although information con- 
cerning a potential role for 1,2-diacylglycerol in inhibition 
of apoptosis via ceramide synthase is not yet available, 
understanding the modes and temporal patterns of the 
generation of pro- and anti-apoptotic signals would appear 
to be essential for understanding the mechanisms of cell 
kill by lethal agents. 
In sum, the present studies provide evidence for a 
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causal  role for  ceramide  generat ion  in daunorubic in-  
induced apoptos is .  The apparent  critical role for ceramide 
generat ion in apoptos is  in response  to mult iple d iverse 
stimuli, inc luding Fas, TNF(~, ionizing radiat ion,  and the 
chemotherapeut ic  agent  daunorub ic in ,  suggests  that cer- 
amide may serve  as a gener ic  s ignal  for  apoptot ic  cell 
death.  In fact, the inhibit ion of  apoptos is  by the specif ic 
ceramide synthase  inhibitor fumonis in  B1 const i tutes de- 
f init ive ev idence for  a requ i rement  for ceramide  in the in- 
duct ion of the apoptot ic  response.  The  recogni t ion of pleio- 
tropic mechan isms leading to ceramide  generat ion  and 
an improved unders tand ing  of  the molecu lar  basis of 
apoptos is  may have important  impl icat ions for  pharmaco-  
logic intervent ion in the s ignal ing processes  that regulate 
auto immune d iseases  and cancer.  
Experimental Procedures 
Cell Culture 
P388 murine leukemia cells (ATCC CCL 46) were grown in RPM11640 
supplemented with 1.67% MEM amino acid solution, 1% MEM nones- 
sential amino acid solution, 1% MEM vitamin solution, 1 mM sodium 
pyruvate, 2 mM glutamine, 8.9 mM sodium bicarbonate, 57 p.M 
J~-mercaptoethanol, and 10% fetal calf serum. Amino acid solutions, 
MEM vitamin solutions, and serum were obtained from GIBCO BRL. 
Cells were grown at 37°C in a 5% CO2 atmosphere and maintained 
in log phase. U937 human monoblastic leukemia cells were grown in 
RPMI 1640 containing 10% fetal calf serum and 2 mM glutamine. 
Otherwise these cells were handled identically to P388 cells. Cell num- 
bers were determined using a Coulter counter, model Zf (Coulter Elec- 
tronics) and verified by hemacytometer (Hausser Scientific). Cell viabil- 
ity was assessed by trypan blue exclusion analysis. Daunorubicin 
hydrochloride (Sigma) was prepared as a 1 mg/ml stock solution in 
sterile saline and frozen until time of use. 
Cytochemical Staining of Apoptotic Cells 
Morphological changes in the nuclear chromatin of cells undergoing 
apoptosis were detected by staining with the DNA-binding fluoro- 
chrome bis-benzimide (Hoechst 33258; Sigma) as previously de- 
scribed (Oberhammer et al., 1992). In brief, 0.5 x 106 to 3.0 x 10 ~ 
cells were pelleted at 300 x g for 10 rain and washed once with 
phoslShate-buffered saline (PBS). Cells were resuspended in 50 p,I 
of 3% paraformaldehyde in PBS and incubated for 10 rain at room 
temperature. The fixative was removed, and cells were washed once 
in PBS and were resuspended in 15 ~1 of PBS containing t6 ~g/mt 
bis-benzimide. Following a 15 min incubation at room temperature, a
10 Id aliquot was placed on a glass slide, and 500 cells per slide were 
scored for the incidence of apoptotic chromatin changes under an 
Olympus BH2 fluorescence microscope with a BH2-DMU2UV Dich 
Mirror cube filter. Cells with three or more chromatin fragments were 
considered apoptotic. 
Agarose Gel Electrophoresis for DNA Fragmentation 
Oligonucleosomal fragmentation of genomic DNA was determined as 
previously described (Wyllie, 1980). Cells (6 x 106 to 12 x 106) were 
lysed in 1 ml of Nicoletti lysis buffer (10 mM Tris [pH 7.5], 100 mM NaCI, 
1 mM EDTA, 1% sodium dodecyl sulfate, and 50 p.g/ml proteinase K 
[Boerhinger Mannheim]) and incubated at 43°C for at least 10 hr. 
DNA was extracted with an equal volume of phenol, followed by a 
chloroform:isoamyl alcohol extraction. The aqueous phase was then 
treated with 40 pg/ml RNase Plus (5'-3', Incorporated) for 2 hr and 
extracted with phenohchloroform:isoamyl alcohol. The DNA was pre- 
cipitated with 0.5 M NaCI and 95% ethanol overnight at -20°C. DNA 
pellets were resuspended in 90 p~l of TAE buffer (40 mM Tris-acetate 
[pH 8.3], 1 mM EDTA). DNA from each sample (10 p,g) was electropho- 
resed at 80 V for 4 hr through a 2.0% agarose gel in TAE buffer. 
DNA bands were visualized under UV light after staining with ethidium 
bromide. A 123 bp DNA ladder (GIBCO BRL) was used as molecular 
size marker. 
Lipid Analogs 
C2-ceramide (N-acetyl sphingosine), C8-ceramide (N-octanoyl sphin- 
gosine), and 1,2-dioctanoyl-sn-glycerol were obtained from Biomol, 
and stock solutions were prepared in dimethyl sulfoxide. C2-dihy- 
droceramide (N-acetyl dihydrosphingosine) and arachidonic acid, 
which were obtained from Biomoi, and 1,2-dioctanoyl-sn-glycero- 
3-phosphate, which was obtained from Avanti Polar Lipide, were pre- 
pared as stock solutions in 100% ethanol. The final concentrations 
of dimethylsuifoxide and ethanol in the incubations were 0.2% and 
0.1%, respectively, which did not induce apoptosis. Fumonisin B1, 
which was provided by Dr. A. H. Merrill (Emory University) or pur- 
chased from Sigma, was dissolved in sterile water. 
Lipid Studies 
Ceramide was quantified by the diacylglycerol kinase assay as de- 
scribed previously (Dressier and Kolesnick, 1990). in brief, following 
incubation with daunorubicin, cells were pelleted by centrifugation 
(300 x g for 10 min), washed twice with ice cold PBS, and extracted 
with 6 ml of chloroform:methanol:l N HCI (100:100:1, v/v/v). Lipide in 
the organic-phase xtract were dried under N2 and subjected to mild 
alkaline hydrolysis (0.1 N methanolic KOH for 1 hr at 37°C) to remove 
glycerophospholipids. Samples were reextracted, and the organic 
phase was dried under N2. Ceramide contained in each sample was 
resuspended in a 100 I~1 reaction mixture containing 150 pg of cardio- 
lipin (Avanti Polar Lipide), 280 ~M diethylenetriaminepentaacetic acid 
(DTPA; Sigma), 51 mM octyl-~-D-glucopyranoside (Calbiochem), 50 
mM. NaCI, 51 mM imidazole, 1 mM EDTA, 12.5 mM MgCI2, 2 mM 
dithiothreitol, 0.7% glycerol, 70 p.M 13-mercaptoethanol, 1 mM ATP, 
10 p.Ci of ['y-32P]ATP (3000 Ci/mmol; Dupont New England Nuclear), 
35 p,g/ml Escherichia coil diacylglycerol kinase (Calbiochem) at pH 
6.5. After 30 min at room temperature, the reaction was stopped by 
extraction of lipide with 1 ml of chloroform:methanoi:l N HCI (100: 
100:1), 170 id of buffered saline solution (BSS) (135 mM NaCI, 1.5 
mM CaCI2, 0.5 mM MgCI2, 5.6 mM glucose, and 10 mM HEPES [pH 
7.2]), and 30 p.I of 100 mM EDTA. The lower organic phase was dried 
under N2. Ceramide 1-phosphate was resolved by thin-layer chroma- 
tography on silica gel 60 plates (Whatman) using a solvent system of 
chloroform:methanol:acetic acid (65:15:5) and detected by autoradiog- 
raphy, and incorporated 32p was quantified by liquid scintillation count- 
ing. The level of ceramide was determined by comparison with a stan- 
dard curve generated concomitantly of known amounts of ceramide 
(ceramide type III; Sigma). Diacyiglycerol was quantified in a similar 
manner to ceramide, except the alkaline hydrolysis step was omitted. 
Changes in sphingomyelin levels were measured by labeling cells 
to isotopic equilibrium with [3H]choline chloride (79.2 Ci/mmol; Dupont 
New England Nuclear) as previously described (Dressier et al., 1992). 
Cells were incubated with [3H]choline (1.0 p.Ci/ml in tissue culture me- 
dia) for at least three cell doublings. Incubation with daunorubicin, 
extraction, and alkaline hydrolysis of dried lipide were identical to those 
used for ceramide determinations. Sphingomyeiin was resolved from 
residual phosphatidylcholine and lysophosphatidylcholine by thin- 
layer chromatography on silica gel 60 plates using a solvent system 
of chloroform:methanol:acetic a id:water (50:30:8:3), was identified 
by iodine vapor staining, and was quantified by liquid scintillation 
counting. Sphingomyelin mass was verified by lipid phosphorus assay 
(Chen et al., 1956). In brief, sphingomyelin spots were scraped and 
extracted three times with 500 p.I of chloroform:methanohHCI (200: 
100:1), and the combined extracts were dried under N2. Samples were 
refluxed with 50 i~1 of 700/0 perchloric acid for 30 min at 180°C. Color 
reagent (1.0 ml) (0.6 M H2SO4, 0.25% ammonium molybdate, 1% 
ascorbic acid) was added, and samples were incubated at 50°C for 
1 hr. A76o was read, and phosphorus content was determined by com- 
parison with known quantities of Na2HPO4. 
Evaluation of the Ceramide Synthetic Pathway in Intact Cells 
Cells (60 x 108) were pelleted by centrifugation (300 x g for 10 min), 
washed once with BSS, and resuspended in 0.5 ml BSS at room tem- 
perature. [1-~'C]stearic acid (12 p.Ci; 51 mCi/mmol; ICN Pharmaceuti- 
cals) was dried under N2, resuspended in 100 p.I of BSS with sonication, 
and added to the cell suspension to start the reaction. At the indicated 
times, a 30 p.I aliquot containing 3 x 108 cells was diluted into 1.0 ml 
of ice cold BSS to stop incorporation. Each sample was pelleted at 
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300 x g for 10 min, and cellular lipids were extracted and subjected 
to mild alkaline hydrolysis as described above. ~4C-labeled ceramide 
was resolved by thin-layer chromatography on silica gel 60 plates 
(Whatman) using a solvent system of chloroform:methanol:acetic acid 
(94:2:4), detected by comigration with ceramide standards, and quanti- 
fied by liquid scintillation counting. Nonspecific incorporation was de- 
termined at 0°C. 
Ceramide Synthase Assay 
Microsomal membranes were prepared as previously described (Liu 
et al., 1994). In brief, 75 x 106 cells were pelleted, washed once with 
cold PBS, and resuspended in 300 I~1 of homogenization buffer (25 
mM HEPES [pH 7.4], 5 mM EGTA, 50 mM NaF, and 10 p.g/ml each 
of leupeptin and soybean trypsin inhibitor). Cells were disrupted using 
a motor-driven 7 ml Tenbroeck tissue homogenizer (Bellco Glass), 
and lysates were centrifuged at 800 x g for 5 min. The postnuclear 
supernate was centrifuged at 250,000 x g for 30 min. The microsomal 
membrane pellet was resuspended in 1.0 ml of homogenization buffer. 
Membranes were prepared fresh daily. 
Assays of ceramide synthase (EC 2.3.1.24) activity were based on 
the procedure of Harel and Futerman (1993). Microsomal membrane 
protein (75 ~g) was incubated in a 1.0 ml reaction mixture containing 
2 mM MgCI2, 20 mM HEPES (pH 7.4), 20 p.M defatted bovine serum 
albumin (Sigma), varying concentrations (0.2-20 ~M) of dihydrosphin- 
gosine (sphinganine; Biomot), 70 p.M unlabeled palmitoyl-coenzyme 
A (Sigma), and 3.6 I~M (0.2 p.Ci) [1J'C]palmitoyl-coenzyme A (55 mCi/ 
mmol; American Radiolabeled Chemicals). Dihydrosphingosine was 
dried under N2 from a stock solution in 100% ethanol and dissolved 
with sonication in the reaction mixture prior to addition of microsomal 
membranes. The reaction was started by addition of palmitoyl-coen- 
zyme A, incubated at 37°C for 1 hr, and then stopped by extraction 
of lipids using 2 ml of chloroform:methanol (1:2). Lower phase (500 
~l) was removed, concentrated under N2, and applied to a silica gel 
60 thin-layer chromatography plate. Dihydroceramide was resolved 
from free radiolabeled fatty acid using a solvent system of chloroform: 
methanoh3.5 N ammonium hydroxide (85:15:1), identified by iodine 
vapor staining based on comigration with ceramide standards, and 
quantified by liquid scintillation counting. The velocity of the reaction 
was linear for at least 2 hr, and the amount of palmitoyl-coenzyme A 
consumed did not exceed 5% of total. 
Protein Determinations 
In intact cell studies, protein determinations were performed using a 
bicinchoninic acid assay kit (Pierce) (Smith et al., 1985) with bovine 
serum albumin standards. Protein determinations on microsomal 
membrane preparations were performed as described by Bradford 
(1976), using the dye reagent purchased from Bio-Rad and bovine 
serum albumin standards. 
Statistical Analysis 
Statistical analysis was performed by Student's ttest, and linear regres- 
sion was performed by the method of least squares. 
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